The CIRMEN (Centre d’Innovation et de Recherche en Médecine Nucléaire) created by CCC in 2016, in close interaction with our UMR Inserm/UdA should be highlighted as being devoted to GMP production, formulation and quality control of radiopharmaceuticals for first into human. Such a structure dedicated to first into human clinical transfer is rare in France and open many research perspectives in radiopharmaceuticals for imaging and targeted therapy. As example, from 2018 CIRMEN is one of the French centers involved in the clinical transfer of 177Lu-PSMA for theranostic management of patients with prostate cancer.

Responsable
Dr Sophie LEVESQUE

Membres